Zkusit zdarma
ImmunityBio, Inc.

ImmunityBio, Inc.

IBRX
Cena:
$ 7.22
-0.52 (-6.72%)
Valuace
100
Růst
30
Zdraví
50
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
IBRX 2-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

IBRX 2-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

17:32 24-05-2026

San Francisco, California--(Newsfile Corp. - May 24, 2026) - ImmunityBio, Inc. (NASDAQ: IBRX) faces ...

IBRX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

16:47 24-05-2026

New York, New York--(Newsfile Corp. - May 24, 2026) - WHY: Rosen Law Firm, a global investor rights...

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

12:00 24-05-2026

NEW YORK, May 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz and Grossman, LLC, a nationally recogn...

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

20:00 23-05-2026

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, I...

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

IBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

19:37 23-05-2026

NEW YORK, May 23, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi...

IBRX IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

16:42 23-05-2026

New York, New York--(Newsfile Corp. - May 23, 2026) - WHY: Rosen Law Firm, a global investor rights...

IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

11:53 23-05-2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff...

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

10:00 23-05-2026

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B M...

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

9:41 23-05-2026

IBRX Investors with Losses Encouraged to Contact the Firm BeforeMay 26th Deadline SAN FRANCISCO, May...

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

18:11 22-05-2026

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, r...

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

17:25 22-05-2026

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the for...

IBRX DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

16:37 22-05-2026

New York, New York--(Newsfile Corp. - May 22, 2026) - WHY: Rosen Law Firm, a global investor rights...

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

16:05 22-05-2026

Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L...

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

16:05 22-05-2026

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffere...

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

15:08 22-05-2026

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm...

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

14:00 22-05-2026

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kess...

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

13:09 22-05-2026

Did you buy IBRX securities between January 19, 2026, and March 24, 202 6? Affected IBRX Investor Su...

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

12:48 22-05-2026

SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities ...

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

12:00 22-05-2026

BENSALEM, Pa., May 22, 2026 /PRNewswire/ -- The Law Offices of Howard G....

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

12:00 22-05-2026

New York, New York--(Newsfile Corp. - May 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a national...

close

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. - IBRX

12-02-2026
NEW YORK, FEB. 12, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

IMMUNITYBIO LAUNCHES PHASE 2 CHEMOTHERAPY-FREE CAR-NK CELL THERAPY TRIAL WITH ANKTIVA® (RESQ215B) IN INDOLENT LYMPHOMAS

02-02-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHE...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. - IBRX

29-01-2026
NEW YORK, JAN. 29, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF IMMUNITYBIO, INC. - IBRX

27-01-2026
NEW YORK, JAN. 27, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY

23-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHE...
Více zde

IMMUNITYBIO ADVANCES REGULATORY DISCUSSIONS WITH FDA ON POTENTIAL RESUBMISSION PATH FOR ANKTIVA® IN BCG-UNRESPONSIVE PAPILLARY BLADDER CANCER

20-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A CLINICAL-STAGE IMMUNOTHERA...
Více zde

IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG

16-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX) TODAY ANNOUNCED AN UPDATE ON ...
Více zde

IMMUNITYBIO REPORTS CONTINUED EXECUTION AND SALES MOMENTUM WITH $113 MILLION OF PRELIMINARY NET PRODUCT REVENUE—A 700% INCREASE YEAR-OVER-YEAR

15-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A VERTICALLY-INTEGRATED COMM...
Více zde

SAUDI FDA GRANTS ACCELERATED APPROVAL TO IMMUNITYBIO'S ANKTIVA® FOR NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN-SITU

14-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHE...
Více zde

IMMUNITYBIO ANNOUNCES POSITIVE RESULTS DEMONSTRATING ANKTIVA® AS A LYMPHOCYTE STIMULATING AGENT IN COMBINATION WITH CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER

13-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A CLINICAL-STAGE IMMUNOTHERA...
Více zde

NANTWORKS AND IMMUNITYBIO ANNOUNCE INAUGURAL U.S.-SAUDI BIOTECH ALLIANCE SUMMIT TO ADVANCE IMMUNOTHERAPY 2.0 AND GLOBAL HEALTH SECURITY

12-01-2026
CULVER CITY, CALIF.--(BUSINESS WIRE)--NANTWORKS, LLC, AND IMMUNITYBIO, INC. (NASDAQ: IBRX), TODAY AN...
Více zde

IMMUNITYBIO FOUNDER DR. PATRICK SOON-SHIONG RECOGNIZED AS ONE OF “100 MOST INFLUENTIAL PEOPLE IN ONCOLOGY IN 2025”

29-12-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A COMMERCIAL-STAGE IMMUNOTHE...
Více zde

ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY NON-MUSCLE INVASIVE BLADDER CANCER

16-12-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO RECEIVES CONDITIONAL MARKETING AUTHORIZATION RECOMMENDATION FROM THE EUROPEAN MEDICINES AGENCY FOR ANKTIVA® WITH BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU—A FIRST IN EUROPE

12-12-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMPANY, A...
Více zde

NEW SURVEY REVEALS NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS SEEK MORE CARE CONVERSATIONS

13-11-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--A NEW U.S. SURVEY CONDUCTED BY THE HARRIS POLL ON BEHALF OF IM...
Více zde

DRIVEN BY STRONG DEMAND, IMMUNITYBIO REPORTS 467% YEAR-TO-DATE UNIT GROWTH AND $75 MILLION IN SALES YEAR-TO-DATE, UP 434% FROM Q3 2024

04-11-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO'S ANKTIVA® REVERSES LYMPHOPENIA AND EXTENDS OVERALL SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RESISTANT TO CHECKPOINT THERAPY

08-09-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

INITIAL DATA SHOWS 100% DISEASE CONTROL IN 5 OUT OF 5 PATIENTS WITH RECURRENT GLIOBLASTOMA WITH TWO PATIENTS IN NEAR COMPLETE RESPONSE TREATED WITH IMMUNITYBIO'S ANKTIVA®, NK CELL THERAPY PLUS OPTUNE GIO® DEVICE

26-08-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO ANNOUNCES PHASE 2 STUDY OF ANKTIVA® IN PATIENTS WITH LONG COVID

19-08-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO REPORTS COMPLETE RESPONSES IN NON-HODGKIN WALDENSTROM LYMPHOMA PATIENTS WITH CHEMOTHERAPY-FREE, FIRST-IN-CLASS CD19 CAR-NK IMMUNOTHERAPY

13-08-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMPANY, A...
Více zde

IMMUNITYBIO ANNOUNCES HOUSTON'S MICHAEL E. DEBAKEY VA MEDICAL CENTER IS AMONG THE FIRST VA HOSPITALS TO ADMINISTER ANKTIVA® TO BLADDER CANCER PATIENTS

11-08-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO REPORTS Q2 EARNINGS RELEASE REFLECTING 60% INCREASE IN REVENUE IN Q2 2025, WITH YEAR-TO-DATE SALES OF $43 MILLION AND 246% UNIT GROWTH SINCE J-CODE

05-08-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO, INC. ANNOUNCES EXECUTION OF $80 MILLION EQUITY FINANCING FROM MULTIPLE INSTITUTIONAL INVESTORS

25-07-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO REPORTS 60% INCREASE IN REVENUE IN Q2 2025, WITH YEAR-TO-DATE SALES OF $43 MILLION AND 246% UNIT GROWTH SINCE J-CODE WITH REGULATORY UPDATES

25-07-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

UK MHRA APPROVES IMMUNITYBIO'S ANKTIVA® PLUS BCG FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN SITU

07-07-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX) TODAY ANNOUNCED THAT THE UK M...
Více zde

ASCO REPORT OF PIONEERING TREATMENT OF LYMPHOPENIA WITH SIGNIFICANT OVERALL SURVIVAL BENEFIT IN ADVANCED PANCREATIC CANCER

03-06-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX) TODAY ANNOUNCED RESULTS PRESE...
Více zde

IMMUNITYBIO RECEIVES FDA EXPANDED ACCESS AUTHORIZATION FOR LANDMARK TREATMENT OF LYMPHOPENIA WITH ANKTIVA®, THE CANCER BIOSHIELD™ PLATFORM, IN PATIENTS WITH SOLID TUMORS

02-06-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO, SAUDI ARABIA'S MINISTRY OF INVESTMENT, KFSHRC, AND KAIMRC SIGN STRATEGIC MEMORANDUM OF UNDERSTANDING TO LAUNCH CANCER BIOSHIELD™ PLATFORM IN THE MIDDLE EAST

27-05-2025
CULVER CITY, CALIF. & RIYADH, SAUDI ARABIA--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEA...
Více zde

IMMUNITYBIO REPORTS DOUBLED NET REVENUE AND 150% UNIT GROWTH IN Q1 2025, WITH CONTINUED STRONG SALES MOMENTUM IN FIRST QUARTER SINCE J-CODE

12-05-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

IMMUNITYBIO REQUESTS AN URGENT MEETING WITH FDA TO ADDRESS THE CHANGE IN THE AGENCY'S UNAMBIGUOUS GUIDANCE ON JAN 2025 TO SUBMIT A SBLA FOR NMIBC BCG UNRESPONSIVE PAPILLARY DISEASE, FOLLOWING AN INCONSISTENT REFUSAL TO FILE LETTER ON MAY 2, 2025

05-05-2025
CULVER CITY, CALIF.--(BUSINESS WIRE)--IMMUNITYBIO, INC. (NASDAQ: IBRX), A LEADING IMMUNOTHERAPY COMP...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-26 00:00:008-KStáhnout
2026-01-15 00:00:008-KStáhnout
2026-01-14 00:00:008-KStáhnout
2025-12-29 00:00:008-KStáhnout
2025-12-15 00:00:008-KStáhnout
2025-12-12 00:00:008-KStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-05 00:00:0010-QStáhnout
2025-08-08 01:00:008-KStáhnout
2025-08-08 00:00:008-KStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:008-KStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-07-25 01:00:008-KStáhnout
2025-07-25 00:00:008-KStáhnout
2025-06-20 01:00:008-KStáhnout
2025-06-20 00:00:008-KStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 01:00:0010-QStáhnout
2025-05-12 00:00:008-KStáhnout
2025-05-12 00:00:0010-QStáhnout
2025-05-05 01:00:008-KStáhnout
2025-05-05 00:00:008-KStáhnout
2025-04-15 01:00:008-KStáhnout
2025-04-15 00:00:008-KStáhnout
2025-04-08 01:00:008-KStáhnout
2025-04-08 00:00:008-KStáhnout
2025-03-19 00:00:008-KStáhnout
2025-03-18 23:00:008-KStáhnout
2025-03-03 00:00:008-KStáhnout
2025-03-03 00:00:0010-KStáhnout
2025-03-02 23:00:008-KStáhnout
2025-03-02 23:00:0010-KStáhnout
2025-02-13 00:00:008-KStáhnout
2025-02-12 23:00:008-KStáhnout
2025-02-07 00:00:008-KStáhnout
2025-02-06 23:00:008-KStáhnout
2024-12-11 00:00:008-KStáhnout
2024-12-10 23:00:008-KStáhnout
2024-12-10 00:00:008-KStáhnout
2024-12-09 23:00:008-KStáhnout
2024-11-19 00:00:008-KStáhnout
2024-11-18 23:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-08-12 01:00:0010-QStáhnout
2024-08-12 00:00:0010-QStáhnout
2024-07-18 01:00:008-KStáhnout
2024-07-18 00:00:008-KStáhnout
2024-06-12 01:00:008-KStáhnout
2024-06-12 00:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-04-23 01:00:008-KStáhnout
2024-04-23 00:00:008-KStáhnout
2024-03-19 00:00:0010-KStáhnout
2024-03-18 23:00:0010-KStáhnout
2024-02-26 00:00:008-KStáhnout
2024-02-25 23:00:008-KStáhnout
2024-01-02 00:00:008-KStáhnout
2024-01-01 23:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-09-11 01:00:008-KStáhnout
2023-09-11 00:00:008-KStáhnout
2023-09-01 01:00:008-KStáhnout
2023-09-01 00:00:008-KStáhnout
2023-08-15 01:00:008-KStáhnout
2023-08-15 00:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-07-21 01:00:008-KStáhnout
2023-07-21 00:00:008-KStáhnout
2023-07-20 01:00:008-KStáhnout
2023-07-20 00:00:008-KStáhnout
2023-06-14 01:00:008-KStáhnout
2023-06-14 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-03-31 01:00:008-KStáhnout
2023-03-31 00:00:008-KStáhnout
2023-03-20 00:00:008-KStáhnout
2023-03-19 23:00:008-KStáhnout
2023-03-01 00:00:0010-KStáhnout
2023-02-28 23:00:0010-KStáhnout
2023-02-15 00:00:008-KStáhnout
2023-02-14 23:00:008-KStáhnout
2023-02-14 00:00:008-KStáhnout
2023-02-13 23:00:008-KStáhnout
2023-02-13 00:00:008-KStáhnout
2023-02-12 23:00:008-KStáhnout
2022-12-12 00:00:008-KStáhnout
2022-12-11 23:00:008-KStáhnout
2022-12-05 00:00:008-KStáhnout
2022-12-04 23:00:008-KStáhnout
2022-11-15 00:00:008-KStáhnout
2022-11-14 23:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-09-02 01:00:008-KStáhnout
2022-09-02 00:00:008-KStáhnout
2022-08-08 01:00:0010-QStáhnout
2022-08-08 00:00:0010-QStáhnout
2022-06-14 01:00:008-KStáhnout
2022-06-14 00:00:008-KStáhnout
2022-05-10 01:00:0010-QStáhnout
2022-05-10 00:00:0010-QStáhnout
2022-03-25 00:00:008-KStáhnout
2022-03-24 23:00:008-KStáhnout
2022-03-01 00:00:0010-KStáhnout
2022-02-28 23:00:0010-KStáhnout
2022-02-15 00:00:008-KStáhnout
2022-02-14 23:00:008-KStáhnout
2022-01-12 00:00:008-KStáhnout
2022-01-11 23:00:008-KStáhnout
2021-12-20 00:00:008-KStáhnout
2021-12-19 23:00:008-KStáhnout
2021-11-12 00:00:0010-QStáhnout
2021-11-11 23:00:0010-QStáhnout
2021-09-27 01:00:008-KStáhnout
2021-09-27 00:00:008-KStáhnout
2021-09-13 01:00:008-KStáhnout
2021-09-13 00:00:008-KStáhnout
2021-08-13 01:00:008-KStáhnout
2021-08-13 00:00:008-KStáhnout
2021-08-12 01:00:0010-QStáhnout
2021-08-12 00:00:0010-QStáhnout
2021-06-15 01:00:008-KStáhnout
2021-06-15 00:00:008-KStáhnout
2021-06-11 01:00:008-KStáhnout
2021-06-11 00:00:008-KStáhnout
2021-06-04 01:00:008-KStáhnout
2021-06-04 00:00:008-KStáhnout
2021-05-28 01:00:008-KStáhnout
2021-05-28 00:00:008-KStáhnout
2021-05-14 01:00:0010-QStáhnout
2021-05-14 00:00:0010-QStáhnout
2021-05-03 01:00:008-KStáhnout
2021-05-03 00:00:008-KStáhnout
2021-04-01 01:00:008-KStáhnout
2021-04-01 00:00:008-KStáhnout
2021-03-17 00:00:008-KStáhnout
2021-03-16 23:00:008-KStáhnout
2021-03-10 00:00:008-KStáhnout
2021-03-09 23:00:008-KStáhnout
2021-03-04 00:00:0010-KStáhnout
2021-03-03 23:00:0010-KStáhnout
2021-02-25 00:00:008-KStáhnout
2021-02-24 23:00:008-KStáhnout
2021-02-24 00:00:008-KStáhnout
2021-02-23 23:00:008-KStáhnout
2021-02-10 00:00:008-KStáhnout
2021-02-09 23:00:008-KStáhnout
2021-01-13 00:00:008-KStáhnout
2021-01-12 23:00:008-KStáhnout
2020-12-22 00:00:008-KStáhnout
2020-12-21 23:00:008-KStáhnout
2020-12-21 00:00:008-KStáhnout
2020-12-20 23:00:008-KStáhnout
2020-11-09 00:00:0010-QStáhnout
2020-11-08 23:00:0010-QStáhnout
2020-10-26 00:00:008-KStáhnout
2020-10-25 23:00:008-KStáhnout
2020-08-24 01:00:008-KStáhnout
2020-08-24 00:00:008-KStáhnout
2020-08-07 01:00:0010-QStáhnout
2020-08-07 00:00:0010-QStáhnout
2020-06-25 01:00:008-KStáhnout
2020-06-25 00:00:008-KStáhnout
2020-06-24 01:00:008-KStáhnout
2020-06-24 00:00:008-KStáhnout
2020-06-19 01:00:008-KStáhnout
2020-06-19 00:00:008-KStáhnout
2020-06-12 01:00:008-KStáhnout
2020-06-12 00:00:008-KStáhnout
2020-05-27 01:00:008-KStáhnout
2020-05-27 00:00:008-KStáhnout
2020-05-11 01:00:0010-QStáhnout
2020-05-11 00:00:0010-QStáhnout
2020-03-25 00:00:0010-KStáhnout
2020-03-24 23:00:0010-KStáhnout
2019-11-05 00:00:0010-QStáhnout
2019-11-04 23:00:0010-QStáhnout
2019-08-07 01:00:008-KStáhnout
2019-08-07 00:00:008-KStáhnout
2019-08-06 01:00:0010-QStáhnout
2019-08-06 00:00:0010-QStáhnout
2019-06-10 01:00:008-KStáhnout
2019-06-10 00:00:008-KStáhnout
2019-06-07 01:00:008-KStáhnout
2019-06-07 00:00:008-KStáhnout
2019-05-08 01:00:0010-QStáhnout
2019-05-08 00:00:0010-QStáhnout
2019-03-13 00:00:0010-KStáhnout
2019-03-12 23:00:0010-KStáhnout
2018-11-07 00:00:0010-QStáhnout
2018-11-06 23:00:0010-QStáhnout
2018-08-06 01:00:0010-QStáhnout
2018-08-06 00:00:0010-QStáhnout
2018-06-13 01:00:008-KStáhnout
2018-06-13 00:00:008-KStáhnout
2018-05-07 01:00:0010-QStáhnout
2018-05-07 00:00:0010-QStáhnout
2018-04-17 01:00:008-KStáhnout
2018-04-17 00:00:008-KStáhnout
2018-03-12 00:00:0010-KStáhnout
2018-03-11 23:00:0010-KStáhnout
2017-11-07 00:00:0010-QStáhnout
2017-11-06 23:00:0010-QStáhnout
2017-09-22 01:00:008-KStáhnout
2017-09-22 00:00:008-KStáhnout
2017-08-07 01:00:0010-QStáhnout
2017-08-07 00:00:0010-QStáhnout
2017-06-13 01:00:008-KStáhnout
2017-06-13 00:00:008-KStáhnout
2017-05-08 01:00:0010-QStáhnout
2017-05-08 00:00:0010-QStáhnout
2017-03-15 00:00:0010-KStáhnout
2017-03-14 23:00:0010-KStáhnout
2016-11-10 00:00:0010-QStáhnout
2016-11-09 23:00:0010-QStáhnout
2016-08-29 01:00:008-KStáhnout
2016-08-29 00:00:008-KStáhnout
2016-08-15 01:00:0010-QStáhnout
2016-08-15 00:00:0010-QStáhnout
2016-06-20 01:00:008-KStáhnout
2016-06-20 00:00:008-KStáhnout
2016-05-16 01:00:0010-QStáhnout
2016-05-16 00:00:0010-QStáhnout
2016-03-30 01:00:0010-KStáhnout
2016-03-30 00:00:0010-KStáhnout
2016-03-29 01:00:008-KStáhnout
2016-03-29 00:00:008-KStáhnout
2016-03-11 00:00:008-KStáhnout
2016-03-10 23:00:008-KStáhnout
2016-01-25 00:00:008-KStáhnout
2016-01-24 23:00:008-KStáhnout
2015-11-27 00:00:008-KStáhnout
2015-11-26 23:00:008-KStáhnout
2015-11-17 00:00:008-KStáhnout
2015-11-16 23:00:008-KStáhnout
2015-11-12 00:00:0010-QStáhnout
2015-11-11 23:00:0010-QStáhnout
2015-09-10 01:00:0010-QStáhnout
2015-09-10 00:00:0010-QStáhnout
2015-08-04 01:00:008-KStáhnout
2015-08-04 00:00:008-KStáhnout
preloader